A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
For part a of the trial, participant must have recurrent or refractory non-central nervous system (CNS) Solid Tumors
For part B of the trial, participant must have recurrent or refractory central nervous system (CNS) Tumors
Participants Must Not:
Participant must not have other treatment options
Participant must not have active or recent history of serious bleeding events
Participant must not have active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
Participant must not have active or recent history of dangerously high blood pressure or Headache, convulsions or coma related to high blood pressure
Participant must not have an active, non-healing wound or bone fracture
Participant must not have a history of organ transplant
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo